For the Inventor, By the Inventor

Enter assignee name

Chadstone, Australia

Cellestis Limited

USPTO Granted Patents = 14

CIPO Patents = 1

EPO Patents = 14

Trademarks = 4

Forward Citations = 17

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Francesca Mariani (6 out of 6 patents)

Massimo Amicosante (6 out of 8 patents)

Vittorio Colizzi (6 out of 8 patents)

4. Cesare Saltini (6 out of 6 patents)

5. Jeff Boyle (6 out of 7 patents)

6. Emily Manktelow (2 out of 3 patents)

7. Ashley Knights (2 out of 2 patents)

8. Carmen Munian (2 out of 2 patents)

9. Anthony J Radford (1 out of 2 patents)

10. Jenny Louise Howard (1 out of 2 patents)

11. Rachel De Las Heras (1 out of 1 patent)

12. Stephen L Jones (1 out of 1 patent)

13. Steven Paul Wild (1 out of 1 patent)

14. James Stuart Rothel (1 out of 2 patents)

15. Angela Cosgriff (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 12181476 - Use of amino acid sequences fromor corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom (2024-12-31),

2. 12153042 - Cell mediated immune response assay (2024-11-26),

3. 11841367 - TLR agonist-enhanced in vitro assay of cell mediated immune responsiveness (2023-12-12),

4. 11275086 - Use of amino acid sequences fromor corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom (2022-03-15),

5. 10788491 - Use of amino acid sequences fromor corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom (2020-09-29),

6. 10564150 - Cell mediated immune response assay (2020-02-18),

7. 10551380 - TLR agonist-enhanced in vitro assay of cell mediated immune responsiveness (2020-02-04),

8. 10408833 - Use of amino acid sequences fromor corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom (2019-09-10),

9. 9983207 - Cell mediated immune response assay with enhanced sensitivity (2018-05-29),

10. 9829490 - [object Object] (2017-11-28),

11. 9459253 - Assay for measuring cell-mediated immunoresponsiveness (2016-10-04),

12. 9110061 - Use of amino acid sequences from mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom (2015-08-18),

13. 8871508 - Cell-mediated immune response assay and kits therefor (2014-10-28),

14. 7608392 - Diagnostic assay for measuring a cell mediated immune response (2009-10-27),

Cellestis Limited is a biotechnology company based in Chadstone, Australia, specializing in the development of innovative diagnostic solutions. The company focuses on enhancing the detection and management of infectious diseases, particularly through advanced immunological testing technologies. Cellestis is recognized for its contributions to the field of medical diagnostics, leveraging cutting-edge research to improve patient outcomes and streamline healthcare processes. Its commitment to innovation positions it as a key player in the global biotechnology landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

14 Patents

#1 in Chadstone

#271 in Australia

#42,199 in the World

Chadstone, Australia

Cellestis Limited

Forward Citations = 17

15 inventors:

Francesca Mariani (6 out of 6 patents)

Massimo Amicosante (6 out of 8 patents)

Vittorio Colizzi (6 out of 8 patents)

4. Cesare Saltini (6 out of 6 patents)

5. Jeff Boyle (6 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…